7.12
2.45%
0.17
시간 외 거래:
7.12
전일 마감가:
$6.95
열려 있는:
$7
하루 거래량:
875.96K
Relative Volume:
0.89
시가총액:
$980.57M
수익:
$62.04M
순이익/손실:
$-533.34M
주가수익비율:
-1.5857
EPS:
-4.49
순현금흐름:
$-473.07M
1주 성능:
-11.11%
1개월 성능:
-6.44%
6개월 성능:
-37.38%
1년 성능:
-27.64%
비르 바이오테크 Stock (VIR) Company Profile
명칭
Vir Biotechnology Inc
전화
415-906-4324
주소
1800 OWENS STREET, SAN FRANCISCO, CA
VIR을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
VIR | 7.12 | 980.57M | 62.04M | -533.34M | -473.07M | -4.49 |
VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
비르 바이오테크 Stock (VIR) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-01-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2023-09-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
2023-03-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
2023-02-21 | 업그레이드 | Goldman | Neutral → Buy |
2023-01-27 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
2022-09-14 | 개시 | SVB Leerink | Outperform |
2022-09-09 | 개시 | Morgan Stanley | Underweight |
2022-03-03 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
2021-12-21 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
2021-10-25 | 업그레이드 | JP Morgan | Underweight → Neutral |
2021-09-22 | 다운그레이드 | Goldman | Buy → Neutral |
2021-06-04 | 재개 | Robert W. Baird | Neutral |
2021-01-27 | 다운그레이드 | JP Morgan | Neutral → Underweight |
2021-01-20 | 재확인 | H.C. Wainwright | Buy |
2020-10-05 | 개시 | BofA Securities | Buy |
2020-09-14 | 업그레이드 | Goldman | Neutral → Buy |
2020-09-11 | 업그레이드 | JP Morgan | Underweight → Neutral |
2020-08-20 | 개시 | Needham | Buy |
2020-03-19 | 다운그레이드 | JP Morgan | Neutral → Underweight |
2020-03-13 | 다운그레이드 | Goldman | Buy → Neutral |
2020-02-27 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
2020-02-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2019-11-14 | 개시 | Robert W. Baird | Neutral |
2019-11-05 | 개시 | Barclays | Overweight |
2019-11-05 | 개시 | Cowen | Outperform |
2019-11-05 | 개시 | Goldman | Buy |
2019-11-05 | 개시 | JP Morgan | Overweight |
모두보기
비르 바이오테크 주식(VIR)의 최신 뉴스
Leerink Partnrs Has Bearish Outlook for VIR FY2026 Earnings - MarketBeat
What is HC Wainwright's Estimate for VIR FY2024 Earnings? - MarketBeat
Needham & Company LLC Reiterates Buy Rating for Vir Biotechnology (NASDAQ:VIR) - MarketBeat
Empowered Funds LLC Sells 163,723 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency - BioSpace
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program - BioSpace
VIRVir Biotechnology, Inc. Latest Stock News & Market Updates - StockTitan
Vir's Hepatitis Delta Drug Achieves 100% Response Rate in Phase 2 Trial | VIR Stock News - StockTitan
EMA grants orphan drug status to Vir Biotech hepatitis treatments - Investing.com
EMA grants orphan drug status to Vir Biotech hepatitis treatments By Investing.com - Investing.com Canada
Vir Biotechnology (VIR) Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency - StreetInsider.com
Vir Biotechnology Secures Key EU Orphan Drug Status for Hepatitis Delta Treatment | VIR Stock News - StockTitan
Vir Biotechnology stock hits 52-week low at $7.08 By Investing.com - Investing.com UK
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD the Liver Meeting - Marketscreener.com
Vir Biotechnology (NASDAQ:VIR) Shares Down 7.4%Here's Why - MarketBeat
(VIR) Proactive Strategies - Stock Traders Daily
What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Yahoo Finance
Promising hepatitis B treatment data presented by Vir Biotechnology - Investing.com
Vir Biotechnology Inc. (VIR) Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations - StreetInsider.com
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting - Business Wire
Baillie Gifford & Co. Reduces Position in Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat
Vir Biotechnology's EVP sells shares worth $44,453 - Investing.com India
Vir Biotechnology's EVP sells shares worth $44,453 By Investing.com - Investing.com UK
Vir Biotechnology EVP vanina de Verneuil sells $32,332 in shares - Investing.com India
Leerink Partnrs Has Negative Outlook of VIR FY2024 Earnings - MarketBeat
HC Wainwright Expects Lower Earnings for Vir Biotechnology - MarketBeat
Vir Biotechnology, Inc. (NASDAQ:VIR) Q3 2024 Earnings Call Transcript - MSN
Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off (NASDAQ:VIR) - Seeking Alpha
VIR Biotechnology's SWOT analysis: stock poised for growth amid challenges - Investing.com India
VIR Biotechnology's SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com Nigeria
Vir Biotechnology EVP vanina de Verneuil sells $32,332 in shares By Investing.com - Investing.com Canada
Trading (VIR) With Integrated Risk Controls - Stock Traders Daily
HC Wainwright Reiterates "Buy" Rating for Vir Biotechnology (NASDAQ:VIR) - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Price Target Cut to $26.00 by Analysts at Barclays - MarketBeat
Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts - Simply Wall St
Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results - Yahoo Finance
Vir Biotechnology Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates - MSN
Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ... By GuruFocus - Investing.com Canada
Vir Biotechnology (NASDAQ:VIR) Posts Quarterly Earnings Results, Misses Estimates By $0.51 EPS - MarketBeat
Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ... - Yahoo Finance
Vir Biotechnology Q3 2024 Earnings Preview - MSN
Earnings call: Vir Biotechnology advances with Sanofi deal, hepatitis trials By Investing.com - Investing.com South Africa
Stock Traders Buy High Volume of Call Options on Vir Biotechnology (NASDAQ:VIR) - MarketBeat
Earnings call: Vir Biotechnology advances with Sanofi deal, hepatitis trials - Investing.com
Vir Biotechnology (NASDAQ:VIR) Shares Gap Down on Disappointing Earnings - MarketBeat
Vir Biotechnology (NASDAQ:VIR) shareholders have endured a 76% loss from investing in the stock three years ago - Yahoo Finance
Vir Biotechnology (NASDAQ:VIR) Earns Buy Rating from Needham & Company LLC - MarketBeat
Vir Biotechnology Reports Q3 2024 Financial Results - TipRanks
Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update - BioSpace
Vir Biotechnology Inc. (VIR) Misses Q3 EPS by 51c - StreetInsider.com
비르 바이오테크 (VIR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):